IQVIA Holdings Inc. $IQV Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 98.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 13,997 shares of the medical research company’s stock after selling 714,501 shares during the period. Pacer Advisors Inc.’s holdings in IQVIA were worth $3,155,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC boosted its position in IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC lifted its stake in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of IQVIA in the 2nd quarter valued at $514,000. First Trust Advisors LP grew its position in IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after buying an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC raised its position in shares of IQVIA by 5.4% in the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after acquiring an additional 1,155 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of several recent analyst reports. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Royal Bank Of Canada began coverage on IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and increased their target price for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Finally, HSBC set a $210.00 price target on shares of IQVIA in a research note on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $222.56.

IQVIA Price Performance

Shares of IQVIA stock opened at $171.21 on Wednesday. The stock has a market capitalization of $28.57 billion, a P/E ratio of 21.22, a PEG ratio of 1.44 and a beta of 1.21. The business has a 50 day simple moving average of $173.68 and a two-hundred day simple moving average of $190.61. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the previous year, the business earned $2.70 earnings per share. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA declared that its board has authorized a stock buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.